(PGNX:Consolidated Issue Listed on NASDAQ Global Select )
John Mendelsohn M.D.
Member of Cancer Scientific Advisory Board, Progenics Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 166 board members in 5 different organizations across 6 different industries.|
See Board Relationships
Dr. John Mendelsohn, M.D., serves as a Director of Greater Houston Partnership. Dr. Mendelsohn has been a Director at Merrimack Pharmaceuticals, Inc. since June 18, 2012. He is the Co-Director of the Sheik Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Dr. Mendelsohn is an internationally recognized leader in cancer research and cancer therapy. He was the President of The University of Texas M. D. Anderson Cancer Center. Dr. Mendelsohn served ...
777 Old Saw Mill River RoadPhone: 914-789-2800
Tarrytown, New York 10591
Board Members Memberships*
Director and Member of Executive Committee
Director and Member of Organization & Compensation Committee
Bachelor's Degree 1958
Harvard Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Jack Lief Ph.D.||Co-Founder, Chairman, Chief Executive Officer, President and Principal Financial Officer|
Arena Pharmaceuticals, Inc.
|Ron Squarer BSc (Biochemistry), MBA||Chief Executive Officer and Director|
Array BioPharma Inc.
|James A. Bianco M.D.||Principal Founder, Chief Executive Officer, President, Executive Director, Member of Scientific Advisory Board and Member of Executive Committee|
CTI BioPharma Corp.
|J. Joseph Kim Ph.D.||Chief Executive Officer, President, Director and Member of Finance Committee|
Inovio Pharmaceuticals, Inc.
|Daniel J. O'Connor Esq.||Chief Executive Officer, President and Director|
|$398.8K||Compensation as of Fiscal Year 2014.|